Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of slug in hepatocellular carcinoma

Carcinogenesis

Volumn 35, Issue 4, 2014, Pages 769-775

  Lee, Hsin Jung ^a   Jeng, Yung Ming ^a,b   Chen, Yu Ling ^a   Chung, Ling ^a   Yuan, Ray Hwang ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AXL PROTEIN; BOSUTINIB; GROWTH ARREST SPECIFIC PROTEIN 6; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR SLUG; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL INVASION; CELL MIGRATION; CLINICAL ARTICLE; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TRANSCRIPTION INITIATION; TUMOR INVASION;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA PRIMERS; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; REAL-TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84898663718     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt372     Document Type: Article

References (36)

1. El-Serag, H.B. et al. (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-2576.
2. Hsu, H.C. et al. (2000) Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am. J. Pathol., 157, 763-770.
3. Hsu, H.C. et al. (1994) Genetic alterations at the splice junction of p53 gene in human hepatocellular carcinoma. Hepatology, 19, 122-128.
4. Llovet, J.M. et al. SHARP Investigators Study Group. (2008) Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 359, 378-390.
5. Jones, S. et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science, 321, 1801-1806.
6. Zhu, A.X. (2012) Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. Semin. Oncol., 39, 493-502.
7. Mínguez, B. et al. (2009) Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr. Opin. Gastroenterol., 25, 186-194.
8. Manning, G. et al. (2002) The protein kinase complement of the human genome. Science, 298, 1912-1934.
9. Stommel, J.M. et al. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science, 318, 287-290.
10. Rescigno, J. et al. (1991) A putative receptor tyrosine kinase with unique structural topology. Oncogene, 6, 1909-1913.
11. Stitt, T.N. et al. (1995) The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell, 80, 661-670.
12. Zhang, Y.X. et al. (2008) AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res., 68, 1905-1915.
13. Wu, C.W. et al. (2002) Clinical significance of AXL kinase family in gastric cancer. Anticancer Res., 22(2B), 1071-1078.
14. Shieh, Y.S. et al. (2005) Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia, 7, 1058-1064.
15. Sainaghi, P.P. et al. (2005) Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J. Cell. Physiol., 204, 36-44.
16. Song, X. et al. (2011) Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer, 117, 734-743.
17. Abba, M.C. et al. (2007) Identification of novel amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse ch8A1 and human ch13q34. Cancer Res., 67, 4104-4112.
18. Linger, R.M. et al. (2008) TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv. Cancer Res., 100, 35-83.
19. Goruppi, S. et al. (1997) Requirement of phosphatidylinositol 3-kinasedependent pathway and Src for Gas6-Axl mitogenic and survival activities in NIH 3T3 fibroblasts. Mol. Cell. Biol., 17, 4442-4453.
20. Stenhoff, J. et al. (2004) Vitamin K-dependent Gas6 activates ERK kinase and stimulates growth of cardiac fibroblasts. Biochem. Biophys. Res. Commun., 319, 871-878.
21. Hector, A. et al. (2010) The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol. Ther., 10, 1009-1018.
22. Stewart, S.A. et al. (2003) Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA, 9, 493-501.
23. Ghosh, A.K. et al. (2011) The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood, 117, 1928-1937.
24. Liu, X. et al. (2011) Insulin-like growth factor I receptor ß expression in hepatocellular carcinoma. Hum. Pathol., 42, 882-891.
25. Harada, K. et al. (1999) Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver, 19, 318-325.
26. Ito, T. et al. (1999) Expression of the Axl receptor tyrosine kinase in human thyroid carcinoma. Thyroid, 9, 563-567.
27. Verma, A. et al. (2011) Targeting Axl and Mer kinases in cancer. Mol. Cancer Ther., 10, 1763-1773.
28. Sun, W.S. et al. (2003) Coexpression of growth arrest-specific gene 6 and receptor tyrosine kinases Axl and Sky in human uterine endometrial cancers. Ann. Oncol., 14, 898-906.
29. D'Arcangelo, D. et al. (2006) Axl receptor activation mediates laminar shear stress anti-apoptotic effects in human endothelial cells. Cardiovasc. Res., 71, 754-763.
30. Seitz, H.M. et al. (2007) Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells. J. Immunol., 178, 5635-5642.
31. Vajkoczy, P. et al. (2006) Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc. Natl Acad. Sci. USA, 103, 5799-5804.
32. Tai, K.Y. et al. (2008) Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1. Oncogene, 27, 4044-4055.
33. Sánchez-Tilló, E. et al. (2012) EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell. Mol. Life Sci., 69, 3429-3456.
34. Chen, H. et al. (2009) Extracellular signal-regulated kinase signaling pathway regulates breast cancer cell migration by maintaining slug expression. Cancer Res., 69, 9228-9235.
35. Giehl, M. et al. (2010) Detection of centrosome aberrations in disease-unrelated cells from patients with tumor treated with tyrosine kinase inhibitors. Eur. J. Haematol., 85, 139-148.
36. Sheridan, C. (2013) First Axl inhibitor enters clinical trials. Nat. Biotechnol., 31, 775-776.